Why the study?
Long-term heart failure therapy involving multiple drug combinations generates substantial direct medical costs among hospitalized patients with comorbid hypertension, creating a need for cost-effectiveness evaluation.
Which pharmacological therapy regimen is most cost-effective for achieving blood pressure targets in hospitalized heart failure patients with comorbid hypertension?
Cross-Sectional (n=58)
No
Which pharmacological therapy regimen is most cost-effective for achieving blood pressure targets in hospitalized heart failure patients with comorbid hypertension?
In hospitalized Indonesian patients with heart failure and comorbid hypertension, the combination of diuretics, ARBs, and beta-blockers was identified as the most cost-effective regimen for achieving blood pressure targets.
Cardiovascular diseases, particularly heart disease with comorbid hypertension, represent a major contributor to increased morbidity, mortality, and healthcare costs, especially among hospitalized patients covered by the Indonesian National Health Insurance (BPJS) in referral hospitals. Long-term heart failure therapy involving multiple drug combinations leads to substantial direct medical costs, highlighting the need for cost-effectiveness evaluation. This study aimed to analyze the cost-effectiveness of pharmacological therapy in hospitalized heart failure patients with comorbid hypertension at RSUD Arifin Achmad, Pekanbaru. This study employed a descriptive quantitative design with a retrospective approach using pharmacoeconomic Cost-Effectiveness Analysis (CEA). Cost-effectiveness was assessed using the Average Cost-Effectiveness Ratio (ACER). A total of 58 patients met the inclusion criteria. The most frequently prescribed therapies were combinations of angiotensin receptor blockers (ARB) with calcium channel blockers (CCB) and diuretics with angiotensin-converting enzyme inhibitors (ACEI) and antiplatelet agents (aspilets), each accounting for 12.06%. Most treatment regimens demonstrated high clinical effectiveness in achieving blood pressure targets. The lowest ACER value was observed in the combination of diuretics, ARB, and β-blockers, amounting to Rp13,950, indicating this regimen as the most cost-effective therapy. The combination of diuretics, ARB, and β-blockers represents the most clinically effective and economically efficient treatment option for hospitalized heart failure patients with comorbid hypertension.
No takes yet. Share an insight, caveat, or question.
Wati et al. (2026) conducted a cross-sectional in Heart failure with comorbid hypertension (n=58). Diuretic + Angiotensin Receptor Blocker (ARB) + Beta-blocker combination therapy vs. Other pharmacological regimens for heart failure with comorbid hypertension was evaluated on Cost-effectiveness assessed by Average Cost-Effectiveness Ratio (ACER) and achievement of JNC VIII target blood pressure (<150/90 mmHg for age >60 years; <140/90 mmHg for age <=60 years) (ACER Rp 13,950).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: